Standard BioTools agrees to sell Microfluidics business to ARCHIMED
Bitget2026/10/05 20:06Standard BioTools agreed to sell its Microfluidics business to healthcare-focused investor ARCHIMED. Closing targeted in about 30 days, subject to customary closing conditions. Microfluidics operations remain within Standard BioTools until the deal closes. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Standard BioTools Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610051605PRIMZONEFULLFEED9839881) on October 05, 2026, and is solely responsible for the information contained therein.
- Standard BioTools agreed to sell its Microfluidics business to healthcare-focused investor ARCHIMED.
- Closing targeted in about 30 days, subject to customary closing conditions.
- Microfluidics operations remain within Standard BioTools until the deal closes.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ-SiriusXM appoints Anjali Sud from Tubi as CEO; stock price rises
A Hyperliquid whale is holding 12,090 AVAX short positions with an unrealized profit of $404,900.
Veteran Investor Is Expecting Biggest XRP Bull Cycle Ever
Crypto prices
More
